{"protocolSection":{"identificationModule":{"nctId":"NCT05752916","orgStudyIdInfo":{"id":"[2022]205"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","officialTitle":"Intravenous Thrombolysis With Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Acute Non-large Vessel Occlusion in Extended Time Window--A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial","acronym":"OPTION"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-06-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-02-09","studyFirstSubmitQcDate":"2023-03-01","studyFirstPostDateStruct":{"date":"2023-03-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-09","lastUpdatePostDateStruct":{"date":"2023-08-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"},"collaborators":[{"name":"Guangzhou Recomgen Biotech Co., Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.","detailedDescription":"OPTION is a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with rhTNK-tPA versus standard of care. A total of 568 patients will be enrolled at approximately 40 centers around China."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["acute ischemic stroke","extended time window","non-large vessel occlusion","intravenous thrombolysis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"prospective, randomized, open label, blinded-endpoint (PROBE)","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":568,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intravenous rhTNK-tPA","type":"EXPERIMENTAL","description":"rhTNK-tPA(0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 5-10 seconds as per the standard manufacturers' instructions for use.","interventionNames":["Drug: rhTNK-tPA"]},{"label":"Antiplatelet agents","type":"ACTIVE_COMPARATOR","description":"Patients will be treated with standard guideline-directed antiplatelet treatment-choice at the discretion of the clinician. Aspirin will be the choice of most physicians; some will choose to use the clopidogrel. Standard of care medication(s) should be given immediately upon randomization.","interventionNames":["Drug: Antiplatelet Agents"]}],"interventions":[{"type":"DRUG","name":"rhTNK-tPA","description":"Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).","armGroupLabels":["Intravenous rhTNK-tPA"]},{"type":"DRUG","name":"Antiplatelet Agents","description":"Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.","armGroupLabels":["Antiplatelet agents"],"otherNames":["Aspirin","Clopidogrel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Excellent functional outcome","description":"Proportion of subjects with mRS 0-1 at 90±7 days","timeFrame":"90±7 days"}],"secondaryOutcomes":[{"measure":"modified Rankin Scale (mRS) score","description":"Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)","timeFrame":"90±7 days"},{"measure":"Good functional outcome","description":"Proportion of subjects with mRS 0-2 at 90±7 days","timeFrame":"90±7 days"},{"measure":"Rate of successful reperfusion","description":"\\>90% reduction of the Tmax\\>6s lesion volumes between the baseline and early follow-up at 24 hours (-2/+12 hours)","timeFrame":"24 hours (-2/+12 hours)"},{"measure":"Change of infarct volume from baseline to 24 hours (-2/+12 hours)","description":"The infarct volume is determined on evaluated on CT at 24 hours (-2/+12 hours)","timeFrame":"24 hours (-2/+12 hours)"},{"measure":"Early clinical recovery","description":"Proportion of subjects with NIHSS score≥8 improved compared with baseline or with NIHSS 0-1 at 24 hours (-2/+12 hours)","timeFrame":"24 hours (-2/+12 hours)"},{"measure":"Change of National Institutes of Health Stroke Scale (NIHSS)","description":"Change of NIHSS score from baseline to 7 days (±2days)","timeFrame":"7±2 days"}],"otherOutcomes":[{"measure":"Incidence of any intracranial hemorrhage","description":"Incidence of any intracranial hemorrhage (Heidelberg criteria) measured at 36 hours","timeFrame":"36 hours"},{"measure":"Incidence of clinically significant intracranial hemorrhage","description":"Incidence of sICH (Heidelberg criteria) measured at 36 hours","timeFrame":"36 hours"},{"measure":"Incidence of major bleeding","description":"Incidence of major bleeding defined as GUSTO severe/life threatening or moderate bleeds measured at 90±7 days","timeFrame":"90±7 days"},{"measure":"All-cause mortality","description":"All-cause mortality at 90±7 days","timeFrame":"90±7 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The clinical diagnosis is acute ischemic stroke (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).\n* Age≥18 years\n* Pre-stroke mRS score≤1 points\n* Baseline NIHSS 4-25 (both included) at the time of randomization\n* Onset (last-seen-well) time to treatment time between 4.5 and 24 hours\n* Informed consent from the patient or surrogate\n* The presence of a Target Mismatch on CT perfusion: ischemic core volume\\<50ml (defined as rCBF\\<30%), mismatch ratio≥1.2 (Tmax\\>6 sec lesion/core volume lesion), mismatch volume≥10ml\n\nExclusion Criteria:\n\n* Treated with intravenous thrombolysis within 72 hours\n* Have a clear contraindication for intravenous thrombolysis\n* Intended to proceed endovascular treatment\n* Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in a NIHSS score\\<4 at randomization\n* Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission\n* Brain tumor (with mass effect)\n* Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency\n* Coagulation Disorders caused by diseases or anticoagulants: warfarin was used with International Normalized Ratio (INR)\\>1.7 or PT\\>15s; heparin was administered within 24 hours; novel oral anticoagulants were used within 48 hours\n* Glycoprotein IIb-IIIa inhibitors were used within the past 72 hours\n* Baseline platelet count \\<100×109/L\n* Known severe renal insufficiency with eGFR\\<30ml/min or serum creatinine\\>2.5mg/dl\n* Undergoing hemodialysis or peritoneal dialysis; known severe intolerance to contrast media\n* Suspected aortic dissection\n* Parenchymal organ surgery or biopsy within the previous 1 month\n* Any active bleeding within the previous 1 month (including gastrointestinal or urinary bleeding)\n* Known severe allergy (more than a rash) to contrast media uncontrolled by medications\n* Refractory hypertension (defined as persistent systolic blood pressure\\>185mmHg or diastolic blood pressure\\>110mmHg)\n* Expected survival time\\<0.5 year (such as complicated with malignant tumor, serious heart and lung diseases, etc.)\n* Participants in other interventional randomized trials that may confound the outcome assessment\n* Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (e.g., inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders)\n\nSpecific Neuroimaging Exclusion Criteria:\n\n* Evidence of acute intracranial hemorrhage\n* Presence of proximal arterial occlusion on CTA/MRA (e.g., intracranial ICA, MCA-M1 and dominant M2 segments, and vertebrobasilar arteries)\n* Ischemic core volume\\>1/3 of the MCA territory defined on CT/MRI","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Junwei Hao, MD","role":"CONTACT","phone":"01083198277","email":"haojunwei@vip.163.com"},{"name":"Gaoting Ma, MD","role":"CONTACT","phone":"18301579891","email":"demo_doctor@163.com"}],"overallOfficials":[{"name":"Junwei Hao, MD","affiliation":"Xuanwu Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Qingfeng Ma, MD","affiliation":"Xuanwu Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Gaoting Ma","role":"CONTACT","phone":"18301579891","email":"demo_doctor@163.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Acute Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077144","term":"Clopidogrel"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"ancestors":[{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","asFound":"Antihypertensive drugs","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}